Home › Cancro dell'endometrio › Texas › San Antonio
Studi clinici su Cancro dell'endometrio a San Antonio, TX
27 studi su Cancro dell'endometrio cercano partecipanti presso sedi a San Antonio e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
In reclutamentoFase 1/2
- New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
In reclutamentoFase 1/2
- NEXT Oncology San Antonio, San Antonio
- START Texas, San Antonio
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
In reclutamentoFase 3
- Texas Oncology-San Antonio Medical Center ( Site 8001), San Antonio
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
In reclutamentoFase 1/2
- START Center for Cancer Research, San Antonio
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
In reclutamentoStudio osservazionale
- The University of Texas Health Science Center at San Antonio, San Antonio
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
In reclutamentoFase 1
- START - San Antonio, San Antonio
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
In reclutamentoFase 3
- USOR - TX Oncology - SA NE, San Antonio
- NEXT San Antonio, San Antonio
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
In reclutamentoFase 3
- Research Site, San Antonio
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
In reclutamentoFase 1
- NEXT San Antonio, San Antonio
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
In reclutamentoFase 1
- UT Health San Antonio - MD Anderson Cancer Center, San Antonio
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
In reclutamentoFase 1
- Normunity Investigational Site, San Antonio
FOG-001 in Locally Advanced or Metastatic Solid Tumors
In reclutamentoFase 1/2
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study of PHST001 in Advanced Solid Tumors
In reclutamentoFase 1
- START Center for Cancer Research - San Antonio, San Antonio
- University of Texas (UT) Health, San Antonio
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
In reclutamentoFase 1/2
- UT Health Mays Cancer Center, San Antonio
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
In reclutamentoFase 1
- START - San Antonio, San Antonio
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
In reclutamentoFase 1/2
- Texas Oncology - San Antonio, San Antonio
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
In reclutamentoFase 3
- Texas Oncology San Antonio Medical Center, San Antonio
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
In reclutamentoFase 1
- NEXT Virginia, LLC, San Antonio
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
In reclutamentoFase 1
- NEXT San Antonio, San Antonio
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
In reclutamentoFase 1/2
- START San Antonio, San Antonio
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
In reclutamentoFase 1
- NEXT Oncology, San Antonio
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
In reclutamentoFase 1/2
- START, San Antonio
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
In reclutamentoFase 1
- NEXT Texas LLC - San Antonio, San Antonio
- START San Antonio, LLC, San Antonio
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
In reclutamentoFase 2
- START San Antonio, San Antonio
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
In reclutamentoFase 1/2
- NEXT Oncology, San Antonio
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
In reclutamentoFase 1
- Dren Investigational Site, San Antonio
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
In reclutamentoFase 2/3
- Texas Oncology-San Antonio Medical Center, San Antonio
Studi su Cancro dell'endometrio in altre città
- Houston, TX68 studi
- New York City, NY52 studi
- Boston, MA50 studi
- Arlington, VA39 studi
- Nashville, TN38 studi
- Los Angeles, CA34 studi
- St. Louis, MO29 studi
- Philadelphia, PA28 studi
- Chicago, IL25 studi
- Columbus, OH25 studi
- Queens, NY25 studi
- Oklahoma City, OK25 studi
Altri studi a San Antonio
- Cancro del polmone non a piccole cellule59 studi
- Cancro colorettale46 studi
- Cancro al seno46 studi
- Cancro metastatico44 studi
- Cancro (tutti i tipi)41 studi
- Obesità40 studi
- Diabete di tipo 237 studi
- Sovrappeso34 studi
- Cancro ovarico31 studi
- Cancro pancreatico31 studi
- Cancro alla prostata28 studi
- Cancro ai polmoni26 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.